-
-
-
-
-
-
-
Immatics (IMTX) Reports FY22 Results, Issues Corporate Update
-
-
-
-
-
-
-
Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
-
-
-
-
-
-
-
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
-
-
-
-
-
-
1,199,636 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

